Who are ABP 501's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adalimumab (ADA), Etanercept via Autoinjector B, Adalimumab treatment arm, Infliximab (Remicade), Adalimumab Ab, TNFa Antagonist - Infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abp-501.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ABP 501 — Competitive Intelligence Brief

ABP 501 (ABP 501) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (biosimilar). Area: Immunology / Rheumatology.

phase 3 TNF-α inhibitor (biosimilar) TNF-α Immunology / Rheumatology Biologic Live · refreshed every 30 min

Target snapshot

ABP 501 (ABP 501) — Amgen. ABP 501 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABP 501 TARGET	ABP 501	Amgen	phase 3	TNF-α inhibitor (biosimilar)	TNF-α
Adalimumab (ADA)	Adalimumab (ADA)	JHSPH Center for Clinical Trials	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Etanercept via Autoinjector B	Etanercept via Autoinjector B	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Adalimumab treatment arm	Adalimumab treatment arm	Medical University of Vienna	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Infliximab (Remicade)	Infliximab (Remicade)	University of California, San Diego	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Adalimumab Ab	Adalimumab Ab	Qilu Hospital of Shandong University	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
TNFa Antagonist - Infliximab	TNFa Antagonist - Infliximab	University of Calgary	marketed	TNF-α antagonist (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (biosimilar) class)

Amgen · 1 drug in this class
CMC Ambroise Paré · 1 drug in this class
Celltrion · 1 drug in this class
Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABP 501 — Competitive Intelligence Brief. https://druglandscape.com/ci/abp-501. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab